← boardnext 2029-02next 2029-05
AVBP
ArriVent BioPharma, Inc.distress 1/10 · well-funded / low risk$30.69+1%today-12% from 52w high
Oncology 2
Lead: EGFR PACC mutant NSCLC · target EGFR
Revenue
pre-revenue
Liquidity
$331M
Runway
2.5 yrs
Shares 1y
+15%
Price & events
+21.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.8%
1D
-6.3%
1W
-9.0%
1M
-1.0%
3M
+32.2%
6M
+40.2%
1Y
+50.2%
2Y
—
5Y
+53.5%
All
Overview
- Market Cap
- $1.43B
- Volume
- 41.26K
- 52 Week Range
- $16.95 – $34.74
- Total Shares
- 46.57M
- Float Shares
- 29.78M
- Short %
- 17.43%
- % Held by Insiders
- 1.63%
- % Held by Institutions
- 96.03%
- RVOL
- 0.07x
- Beta
- 1.30
Pipeline stages · 3 programs
Firmonertinib, EGFR-TKI inhibitor based on investigator's choice
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MRG007
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
furmonertinib 240 mg oral, daily, furmonertinib 160 mg oralEGFR
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-02 Estimated 50% readout ~2029-04-17 | Phase 3 | Firmonertinib, EGFR-TKI inhibitor based on investigator's choicebreakthroughorphan | Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations | — | recruiting |
| 2029-05 Estimated 50% readout ~2029-05-31 | Phase 1 | MRG007 | Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer | — | recruiting |
| 2025-08-15 | Phase 3 | furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral | Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations | 398 | active not recruiting |
| 2025-06-03 | Phase 1 | Furmonertinib | Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I | 160 | active not recruiting |
Catalyst news & presentations · 10
- 2026-08-14earningsEarningsEarnings releaseyahoo
- April 21, 2026conferencedata presentationsecondaryPhase 3firmonertinib · Preclinical poster presentation supporting Phase 3 study.SEC 8-K
- April 20, 2026conferencedata presentationsecondaryARR-002 · Preclinical poster presentation on dual-target ADC.SEC 8-K
- early 2026readoutPhase 3firmonertinib · Topline pivotal Phase 3 FURVENT data projected.SEC 8-K
- second half of 2025trial initiationsecondaryPhase 3firmonertinib · Initiation of randomized global Phase 3 ALPACCA study in first-line PACC patients.SEC 8-K
- September 9, 2025readoutPhase 1firmonertinib · Presentation of final Phase 1b FURTHER trial data at WCLC 2025.SEC 8-K
- first half of 2025regulatory submissionFiled (NDA/BLA)MRG007 · First IND submission planned for 1H 2025SEC 8-K
- 2025-06-23readoutPhase 1/2firmonertinib · Interim readout of global Phase 1b FURTHER trial showing positive efficacy and safety data.SEC 8-K
- 2025-01-21partnershipMRG007 · Exclusive license from Lepu Biopharma for rights outside Greater China; $47M upfront and near-term milestones, up to $1.16B total milestones plus royaltiesSEC 8-K
- September 9, 2024conferencedata presentationsecondaryPhase 1firmonertinib · Presidential Symposium at World Conference on Lung CancerSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $44 (+42% upside) · 11 analysts
- 2026-05-29Truist SecuritiesBuy
- 2026-05-13CitigroupBuy
- 2026-04-24CitigroupBuy
- 2026-03-23B. Riley SecuritiesBuy
- 2026-03-06CitigroupBuy
- 2026-03-06HC Wainwright & Co.Buy
Competitors — EGFR
Recent news
- 2026-07-21ArriVent BioPharma (AVBP) Edges Lower, Testing Support Amid Biotech Volatility - Defined Outcome ETF - dars.gov.et
- 2026-07-15ArriVent’s Firmonertinib Seen as Differentiated EGFR Inhibitor Ahead of FURVENT Readout; Buy Rating Reiterated with Unchanged $42 Price Target - TipRanks
- 2026-07-12(AVBP) Volatility Zones as Tactical Triggers - Stock Traders Daily
- 2026-07-12(AVBP) Volatility Zones as Tactical Triggers - Stock Traders Daily
- 2026-07-12AVBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
- 2026-07-07JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
- 2026-07-06ArriVent’s Emerging CDH17-Targeted ADC Pipeline Supports Maintained Buy Rating and $45 Price Target - TipRanks
- 2026-07-01Price-Driven Insight from (AVBP) for Rule-Based Strategy - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.